 |
|
EtretinatePersistent Serum Levels After Long-term Therapy
John J. DiGiovanna, MD;
Loren A. Zech, MD;
Mark E. Ruddel, PhD;
Gail Gantt, RN;
Gary L. Peck, MD
Arch Dermatol. 1989;125(2):246-251.
Abstract
| |
• In 47 patients who received long-term etretinate therapy, we measured serum etretinate concentrations from one to 244 weeks after the discontinuation of therapy. The earliest posttreatment, nondetectable serum concentration of etretinate was observed at five weeks after treatment. Detectable serum concentrations (0.05 to 1.2 µg/dL) were observed more than two years (108, 111, 131, 136, and 150 weeks) following the discontinuation of therapy. Sequential serum concentrations obtained on eight individual patients were used to determine half-lives for this late-phase elimination. The median half-life for the 12 curves obtained was 12.5 weeks (range, 5.3 to 24.8 weeks). Since etretinate is stored in fat, we compared each patient's deviation from ideal body weight as a measure of excess body fat with various pharmacokinetic factors of etretinate elimination. Overweight patients tended to have slower elimination, maintain higher serum concentrations, and clear etretinate later.
(Arch Dermatol 1989;125:246-251)
Author Affiliations
From the Dermatology Branch (Drs DiGiovanna and Peck and Ms Gantt) and Laboratory of Mathematical Biology (Dr Zech), National Cancer Institute, and Clinical Chemistry (Dr Ruddel), Clinical Center, National Institutes of Health, Bethesda, Md.
Footnotes
Accepted for publication Aug 17, 1988.
Reprint requests to Bldg 10, Room 12N238, Dermatology Branch, National Institutes of Health, Bethesda, MD 20892 (Dr DiGiovanna).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Osteoporosis Is a Toxic Effect of Long-term Etretinate Therapy
DiGiovanna et al.
Arch Dermatol 1995;131:1263-1267.
ABSTRACT
|
